# NME1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *NME1* gene encodes a multifunctional protein with nucleoside diphosphate kinase (NDPK) and 3′–5′ exonuclease activities, crucial for nucleotide metabolism and DNA repair.
- NME1 acts as a tumor metastasis suppressor by repressing genes like MMP2 and VEGFA and also plays a role in DNA damage response through its interaction with the SET complex.
- Activating germline mutations in *NME1* cause Lenz-Majewski syndrome, characterized by craniofacial dysmorphism and skeletal sclerosis, due to hyperactivation of MAPK and BMP signaling pathways.
- Somatic mutations and downregulation of NME1 are observed in aggressive cancers, including neuroblastoma and melanoma, correlating with poor prognosis and increased metastatic potential.
- NME1 interacts with viral oncoproteins from HPV, EBV, and HTLV-1, influencing viral replication, oncogenesis, and host immune evasion mechanisms.
- Therapeutic strategies aim to restore NME1 function in cancer using demethylating agents, HDAC inhibitors, or retinoids, while its inhibition is explored in hematological malignancies with specific small-molecule compounds.

---

## Executive Summary & Key Metadata

The *NME1* gene (also historically designated *NM23-H1*, *NME/NM23 nucleoside diphosphate kinase 1*, and *AWD* in *Drosophila*) encodes a multifunctional protein that operates at the intersection of nucleotide metabolism, signal transduction, transcriptional regulation, and DNA repair. Initially identified through its reduced expression in highly metastatic murine melanoma cell lines, NME1 has since been characterized as a suppressor of tumor metastasis, a histidine-dependent protein kinase, a 3′–5′ exonuclease, and a component of the SET complex involved in DNA damage responses. The protein's dual enzymatic activities—nucleoside diphosphate kinase (NDPK) and nuclease—are structurally partitioned across distinct domains, and its functional pleiotropy is further expanded by homohexameric and heterohexameric assembly with its close paralog NME2.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | NME1 |
| **UniProt Accession** | P15531 |
| **Representative PDB ID** | 1UCN (human NME1 hexamer), 3BBB (NME1–NME2 heterohexamer) |
| **Chromosomal Locus** | 17q21.33 (GRCh38: chr17:49,230,292–49,241,227, minus strand) |
| **Primary Molecular Function** | Nucleoside diphosphate kinase (EC 2.7.4.6); 3′–5′ exonuclease; histidine protein kinase; transcriptional suppressor |
| **Disease & Pathology Associations** | Tumor metastasis suppression (melanoma, breast, hepatocellular carcinoma); neuroblastoma (NDP kinase activity loss); Lenz-Majewski syndrome (activating germline mutations); potential roles in hematological malignancies and viral pathogenesis |
| **Protein Length** | 152 amino acids (isoform 1); 166 amino acids (isoform 2, alternative initiation) |
| **Subcellular Localization** | Cytoplasm, nucleus, plasma membrane (peripheral), mitochondria (reported) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Context and Gene Architecture

The *NME1* gene is located on the long arm of human chromosome 17 at cytogenetic band 17q21.33. In the GRCh38 assembly, the gene spans approximately 10.9 kilobases (kb) of genomic DNA, from position 49,230,292 to 49,241,227 on the minus strand. The locus resides within a gene-dense region that includes several other metastasis-associated and developmental genes, including *NME2* (located immediately telomeric), *NME1-NME2* read-through transcript, *RPS6KB1*, and *TBX21*. The proximity of *NME1* and *NME2* (separated by ~4 kb) is evolutionarily conserved across vertebrates, suggesting shared cis-regulatory elements and coordinated transcriptional control.

The gene comprises 5 exons and 4 introns. Exon 1 is non-coding and contains the primary transcription start site (TSS). The translation initiation codon (ATG) resides in exon 2. Exons 2–5 encode the 152-amino-acid canonical protein. The intron–exon boundaries conform to the GT-AG rule, with phase 0 junctions at introns 1 and 3, and phase 1 at intron 2. The 3′ untranslated region (UTR) in exon 5 is unusually long (~1.2 kb) and contains multiple AU-rich elements (AREs) that mediate mRNA instability in response to cellular stress.

### 1.2 Promoter Architecture and Transcriptional Regulation

The *NME1* promoter lacks a canonical TATA box but contains a high-density CpG island spanning ~1.5 kb upstream of the TSS. This CpG island is subject to dynamic DNA methylation, and its hypomethylation correlates with active transcription in most somatic tissues. The core promoter contains several GC-box motifs that serve as binding sites for the transcription factor Sp1. Functional studies have identified a minimal promoter region spanning nucleotides −110 to +30 relative to the TSS that is sufficient for basal transcriptional activity.

Multiple transcription factor binding sites have been experimentally validated:

- **Sp1/Sp3**: Bind to GC-boxes at positions −60, −45, and −20; required for basal transcription.
- **AP-1 (c-Fos/c-Jun)**: Binds to a TRE-like element at −350; mediates transcriptional induction by phorbol esters and growth factors.
- **NF-κB**: A functional binding site at −280 confers responsiveness to inflammatory cytokines (TNF-α, IL-1β).
- **c-Myc**: Binds to an E-box element (CACGTG) at −180; represses transcription in proliferating cells.
- **p53**: A p53 response element at −520 mediates transcriptional activation following DNA damage.
- **STAT3**: Binds to a GAS-like element at −420; contributes to cytokine-mediated induction.

Enhancer elements have been mapped to an intronic region within intron 1 (coordinates +450 to +700) and to a distal intergenic region ~8 kb upstream of the TSS. The intronic enhancer contains binding sites for C/EBPβ and GATA-1, and its activity is cell-type specific, with highest activity in hematopoietic and epithelial cells. Chromatin conformation capture (Hi-C) data indicate that the *NME1* promoter physically interacts with these enhancer regions in a cell-type-dependent manner, forming a regulatory loop that is disrupted upon differentiation.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of *NME1* generates two major protein-coding isoforms:

- **Isoform 1 (152 aa, P15531-1)**: The canonical NME1 protein. Initiation occurs at the ATG in exon 2. This isoform is the predominant species in most tissues.
- **Isoform 2 (166 aa, P15531-2)**: Generated by use of an alternative upstream in-frame start codon in exon 1, producing a protein with an N-terminal extension of 14 amino acids. This extension contains a putative mitochondrial targeting sequence (MTS) with a predicted amphipathic helix. Isoform 2 is expressed at low levels and localizes to mitochondria, where it may participate in mitochondrial nucleotide pool maintenance.

Additionally, a read-through transcript with *NME2* (designated *NME1-NME2*) is produced by intergenic splicing that removes the polyadenylation signal of *NME1* and joins exon 5 of *NME1* to exon 1 of *NME2*. This chimeric mRNA encodes a fusion protein (NME1-NME2, 309 aa) that retains the NDPK domain of NME1 and the C-terminal portion of NME2. The read-through transcript is subject to nonsense-mediated decay (NMD) under normal conditions but is stabilized in certain cancer cell lines, where it may contribute to altered NDPK activity.

### 1.4 Pseudogenes and Regulatory RNAs

The *NME1* locus has multiple processed pseudogenes dispersed across the genome (e.g., *NME1P1* on chromosome 2, *NME1P2* on chromosome 4), which are transcriptionally silent. Several long non-coding RNAs (lncRNAs) are transcribed from the antisense strand of the *NME1* locus, including *NME1-AS1*. This antisense transcript is upregulated in hepatocellular carcinoma and has been shown to stabilize *NME1* mRNA by forming RNA–RNA duplexes that protect against miRNA-mediated degradation, particularly from miR-26a and miR-30c.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The canonical NME1 protein is 152 amino acids in length with a molecular weight of approximately 17.1 kDa (monomer). The primary sequence can be divided into several functional regions:

| **Region** | **Residues** | **Function** |
|---|---|---|
| N-terminal α-helix (α1) | 1–15 | Hexamer assembly interface; contains phosphorylation site H118 (structural context) |
| β-strand 1 (β1) | 16–22 | Core β-sheet |
| α-helix 2 (α2) | 23–38 | Substrate binding; contains the "lid" region |
| β-strand 2 (β2) | 39–45 | Core β-sheet |
| α-helix 3 (α3) | 46–60 | Hexamer interface; DNA binding |
| β-strand 3 (β3) | 61–67 | Core β-sheet |
| α-helix 4 (α4) | 68–82 | Catalytic cleft; contains D121 (catalytic base) |
| β-strand 4 (β4) | 83–89 | Core β-sheet |
| α-helix 5 (α5) | 90–105 | Hexamer interface; exonuclease active site (N94, H118) |
| β-strand 5 (β5) | 106–112 | Core β-sheet |
| α-helix 6 (α6) | 113–130 | Catalytic cleft; contains H118 (phosphohistidine intermediate) |
| C-terminal tail | 131–152 | Nuclear localization signal (NLS); interaction with SET complex |

### 2.2 Overall Fold and Quaternary Structure

NME1 adopts the canonical NDPK fold: a four-stranded antiparallel β-sheet flanked by α-helices, forming a mixed α/β sandwich. The monomer is roughly 35 Å × 30 Å × 25 Å. The biologically active form is a hexamer arranged as a trimer of dimers, with 32-point group symmetry. The hexamer forms a toroidal structure with a central channel of ~15 Å diameter. Two hexameric forms exist: homohexamers of NME1 and heterohexamers containing both NME1 and NME2 subunits. The heterohexamer is the predominant species in cells where both genes are expressed, and its subunit stoichiometry is variable (e.g., (NME1)₃(NME2)₃ or (NME1)₄(NME2)₂).

The hexamer interface is stabilized by extensive hydrophobic contacts and a network of salt bridges. Key interface residues include L10, V14, L48, V52, I56, L70, I74, L94, and V98. The C-terminal tail (residues 131–152) is disordered in the apo state but becomes ordered upon DNA binding or interaction with partner proteins. This tail contains a bipartite nuclear localization signal (NLS) spanning residues 134–150 (KRK...KRLK), which is recognized by importin-α.

### 2.3 Catalytic Sites and Active Site Architecture

**Nucleoside Diphosphate Kinase (NDPK) Active Site:**

The NDPK catalytic site is located in a cleft between the β-sheet and the α2–α4 helices. The catalytic mechanism proceeds via a ping-pong mechanism:

1. ATP binds to the active site; the γ-phosphate is transferred to the Nε2 atom of H118, forming a phosphohistidine intermediate.
2. The ADP product dissociates.
3. A nucleoside diphosphate (NDP) substrate binds; the phosphate is transferred from H118 to the NDP, yielding a nucleoside triphosphate (NTP).

Key catalytic residues:

- **H118**: The phospho-accepting histidine; mutation to alanine (H118A) abolishes NDPK activity.
- **D121**: Acts as a general base, deprotonating H118 to facilitate nucleophilic attack on the γ-phosphate of ATP.
- **N115, R87, K12**: Coordinate the phosphate groups of the substrate and stabilize the transition state.
- **E52**: Forms a hydrogen bond with the ribose hydroxyl of the substrate, conferring specificity for ribonucleotides over deoxyribonucleotides.

The active site is highly conserved across NDPK family members, and the catalytic histidine is strictly conserved from bacteria to humans.

**3′–5′ Exonuclease Active Site:**

A second, structurally distinct active site mediates the 3′–5′ exonuclease activity of NME1. This site is located on the opposite face of the protein from the NDPK active site, within the α5 helix and adjacent β-strands. The exonuclease activity requires divalent metal ions (Mg²⁺ or Mn²⁺) and cleaves single-stranded DNA or RNA from the 3′ end, releasing mononucleotides. Key residues include N94, H118 (dual role), and D121. Notably, the exonuclease activity is independent of NDPK activity; the H118A mutant retains exonuclease function, while mutations in the exonuclease site (e.g., N94A) abolish nuclease activity without affecting NDPK activity.

The exonuclease activity is implicated in DNA repair and in the cleavage of the SET complex target proteins. NME1 has been shown to nick DNA at sites of UV damage and to participate in base excision repair (BER) by removing 3′ blocking lesions.

### 2.4 DNA Binding and Protein–Protein Interaction Surfaces

NME1 binds to DNA with a preference for single-stranded DNA (ssDNA) and DNA with secondary structures (e.g., G-quadruplexes). The DNA binding surface involves the C-terminal tail (residues 131–152) and the α3 helix (residues 46–60). The NLS within the C-terminal tail is required for DNA binding, and phosphorylation of S122 (by PKC) or S120 (by casein kinase II) modulates DNA affinity.

The SET complex interaction surface maps to the α1 helix and the C-terminal tail. NME1 binds to the SET protein (also known as TAF-Iβ) via a hydrophobic groove on the α1 helix, and this interaction is required for the recruitment of NME1 to chromatin during the DNA damage response.

### 2.5 Post-Translational Modifications

- **Phosphorylation at H118**: The phosphohistidine intermediate is the hallmark of NDPK activity. This modification is labile (half-life ~2 hours at pH 7.5) and can be transferred to other proteins (histidine phosphotransferase activity).
- **Phosphorylation at S120 and S122**: These sites are phosphorylated by protein kinase C (PKC) and casein kinase II (CK2), respectively. Phosphorylation at S122 inhibits DNA binding and promotes nuclear export.
- **Acetylation at K12 and K72**: Acetylation by p300/CBP regulates hexamer stability and NDPK activity.
- **SUMOylation at K135**: SUMOylation promotes nuclear retention and enhances the transcriptional repressor function of NME1.
- **Oxidation of C109**: Reversible oxidation of the sole cysteine residue modulates enzyme activity under oxidative stress conditions.

### 2.6 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load NME1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P15531)

This interactive tool allows users to explore the NME1 hexamer (PDB: 1UCN), highlight the NDPK active site (H118, D121), visualize the exonuclease domain, and examine the C-terminal NLS. Users can toggle between cartoon, surface, and electrostatic potential representations, and can superimpose the NME1–NME2 heterohexamer (PDB: 3BBB) to compare subunit interfaces.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Nucleoside Diphosphate Kinase Activity and Nucleotide Pool Homeostasis

The canonical enzymatic function of NME1 is the reversible phosphorylation of nucleoside diphosphates (NDPs) to nucleoside triphosphates (NTPs) using ATP as the phosphate donor. This activity is essential for maintaining cellular NTP pools, particularly in tissues with high metabolic demand. The enzyme exhibits broad substrate specificity, accepting all canonical ribo- and deoxyribonucleoside diphosphates (ADP, GDP, CDP, UDP, dADP, dGDP, dCDP, dTDP). The kinetic parameters are characterized by a Km for ATP of ~0.1 mM and a kcat of ~1000 s⁻¹ per subunit.

Beyond simple nucleotide interconversion, NME1 contributes to the synthesis of CTP (via phosphorylation of CDP) and UTP, which are rate-limiting for RNA and lipid biosynthesis. In quiescent cells, NME1 activity is low, but it is rapidly induced upon growth factor stimulation, providing the nucleotide precursors required for DNA replication and transcription.

### 3.2 Histidine Protein Kinase and Phosphotransferase Activity

NME1 functions as a histidine protein kinase, transferring the phosphate group from H118 to histidine residues on target proteins. This activity is distinct from the canonical serine/threonine/tyrosine kinases and represents a less-characterized signaling modality. Known substrates include:

- **KSR (Kinase Suppressor of Ras)**: NME1 phosphorylates KSR at H392, which is required for the recruitment of KSR to the plasma membrane and the activation of the MAPK/ERK pathway.
- **AKT1**: NME1 phosphorylates AKT1 at H196, enhancing its kinase activity and promoting cell survival.
- **TRPV5 (Transient Receptor Potential Vanilloid 5)**: NME1 phosphorylates TRPV5 at H711, which is required for channel trafficking to the plasma membrane.
- **ALDH2 (Aldehyde Dehydrogenase 2)**: Phosphorylation at H450 modulates enzyme activity and protects against oxidative stress.

The phosphotransferase activity is regulated by the availability of ATP and by the phosphorylation state of NME1 itself. The half-life of the phosphohistidine on target proteins is typically short (minutes), allowing for rapid signal termination.

### 3.3 Transcriptional Regulation and Gene Expression Control

NME1 acts as a transcriptional suppressor for a subset of genes, particularly those involved in tumor progression and metastasis. The mechanism involves:

1. **Direct DNA binding**: NME1 binds to specific DNA sequences in the promoter regions of target genes, including a GC-rich motif (5′-GGGGCC-3′) and a palindromic sequence (5′-TGACTCA-3′). The binding affinity is enhanced by the presence of the SET complex.
2. **Histone modification**: NME1 recruits histone deacetylases (HDAC1/2) to target promoters, promoting a repressive chromatin state (H3K9me2/3, H3K27me3).
3. **Interaction with transcription factors**: NME1 physically interacts with and inhibits the activity of transcription factors such as c-Myc, AP-1, and NF-κB. For example, NME1 binds to the c-Myc bHLH-ZIP domain, preventing its heterodimerization with Max and thereby blocking Myc-dependent transactivation.

Well-characterized NME1 transcriptional targets include:

- **MMP2 and MMP9** (matrix metalloproteinases): NME1 represses their transcription, reducing extracellular matrix degradation and invasion.
- **VEGFA** (vascular endothelial growth factor A): NME1 suppresses VEGFA expression, inhibiting angiogenesis.
- **CXCR4** (C-X-C chemokine receptor type 4): NME1 downregulates CXCR4, reducing chemotactic responses to SDF-1.
- **TGFB1** (transforming growth factor beta 1): NME1 represses TGFB1, modulating epithelial-mesenchymal transition (EMT).

### 3.4 DNA Repair and Genomic Stability

NME1 participates in multiple DNA repair pathways:

- **Base Excision Repair (BER)**: NME1 possesses 3′–5′ exonuclease activity that removes 3′ blocking lesions (e.g., 3′-phosphate, 3′-phosphoglycolate) generated by reactive oxygen species or ionizing radiation. This activity is essential for the completion of BER, as it generates a ligatable 3′-OH terminus.
- **Nucleotide Excision Repair (NER)**: NME1 is recruited to sites of UV-induced DNA damage, where it nicks the damaged strand and facilitates the excision of the lesion-containing oligonucleotide.
- **Double-Strand Break Repair (DSBR)**: NME1 interacts with the MRN complex (MRE11-RAD50-NBS1) and promotes homologous recombination (HR) by facilitating end resection. NME1 also interacts with BRCA1 and RAD51, and its depletion leads to increased sensitivity to ionizing radiation and PARP inhibitors.

The DNA repair function of NME1 is intimately linked to its role in the SET complex. The SET complex (SET, NME1, NME2, ANP32A, and HMGB2) is a multifunctional assembly that exhibits both histone chaperone and DNA repair activities. Upon DNA damage, the SET complex is cleaved by the protease granzyme A, releasing NME1 and NME2, which then translocate to the nucleus to participate in DNA repair.

### 3.5 Regulation of the MAPK/ERK Pathway

NME1 is a negative regulator of the Ras-MAPK pathway. The mechanism involves:

1. **Direct binding to KSR**: NME1 binds to KSR and inhibits its kinase activity, preventing the phosphorylation of MEK and ERK.
2. **Suppression of Ras activation**: NME1 interacts with the GTPase-activating protein (GAP) neurofibromin, promoting the conversion of Ras-GTP to Ras-GDP.
3. **Transcriptional repression of growth factor receptors**: NME1 suppresses the expression of EGFR and other receptor tyrosine kinases.

The net effect is a reduction in ERK1/2 phosphorylation and a decrease in cell proliferation. This function is particularly relevant in cancer, where NME1 loss leads to hyperactivation of the MAPK pathway.

### 3.6 Protein-Protein Interaction Network

NME1 participates in a dense protein-protein interaction network. Key interactors (from BioGRID and STRING) include:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| NME2 | NDPK isoform; heterohexamer formation | Stable complex |
| SET (TAF-Iβ) | Histone chaperone; DNA repair | Stable complex |
| ANP32A (pp32) | Histone chaperone; tumor suppressor | Stable complex |
| HMGB2 | Chromatin architecture | Stable complex |
| KSR | MAPK scaffold | Transient, phosphorylation-dependent |
| AKT1 | Cell survival kinase | Transient, phosphorylation-dependent |
| BRCA1 | DNA repair | DNA damage-dependent |
| RAD51 | Homologous recombination | DNA damage-dependent |
| MRE11 | DSB sensor | DNA damage-dependent |
| c-Myc | Transcription factor | Stable complex |
| p53 | Tumor suppressor | DNA damage-dependent |
| HDAC1 | Histone deacetylase | Stable complex |
| Importin-α | Nuclear import | Transient |
| Granzyme A | Serine protease | Cleavage substrate |

### 3.7 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant GF as "Growth Factor"
    participant RTK as "Receptor Tyrosine Kinase"
    participant RAS as "Ras-GDP"
    participant NME1 as "NME1"
    participant KSR as "KSR"
    participant MEK as "MEK"
    participant ERK as "ERK"
    participant NUC as "Nucleus"
    participant TF as "Transcription Factors (c-Myc, AP-1)"
    GF->>RTK: Ligand binding
    RTK->>RAS: Activation (GEF-mediated)
    RAS->>KSR: Recruitment to membrane
    NME1->>KSR: Phosphorylation (H392)
    NME1->>RAS: GAP activation (via neurofibromin)
    KSR->>MEK: Phosphorylation
    MEK->>ERK: Phosphorylation
    ERK->>NUC: Translocation
    NUC->>TF: Phosphorylation/Activation
    TF->>NUC: Gene expression (proliferation, invasion)
    NME1->>NUC: Transcriptional repression (HDAC recruitment)
    NUC->>NME1: Target gene silencing (MMP2, VEGFA)
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

NME1 is frequently downregulated in aggressive tumors, but somatic mutations are relatively rare. However, specific mutations have been identified that alter protein function:

| **Mutation** | **Cancer Type** | **Functional Consequence** | **ClinVar Classification** |
|---|---|---|---|
| **P97S** | Breast cancer, melanoma | Disrupts hexamer stability; reduces NDPK activity by ~50%; impairs metastasis suppression | Pathogenic (for metastasis risk) |
| **S120G** | Neuroblastoma (advanced stage) | Reduces NDPK activity; alters DNA binding; promotes nuclear export; associated with poor prognosis | Pathogenic |
| **P97L** | Hepatocellular carcinoma | Similar to P97S; reduces exonuclease activity; impairs DNA repair | Likely pathogenic |
| **R34C** | Colorectal cancer | Disrupts DNA binding; reduces transcriptional repression of MMP2 | Uncertain significance |
| **H118Y** | Rare in cancers | Abolishes NDPK activity; retains exonuclease activity; dominant-negative effect on hexamer | Pathogenic (loss of function) |
| **D121N** | Rare | Abolishes catalytic activity; disrupts metal ion coordination | Pathogenic (loss of function) |
| **K12Q** | Lung cancer | Mimics acetylation; reduces hexamer stability; impairs metastasis suppression | Uncertain significance |

### 4.2 Germline Mutations and Mendelian Disease

**Lenz-Majewski Syndrome (LMS; OMIM #151050):**

Lenz-Majewski syndrome is a rare autosomal dominant disorder characterized by craniofacial dysmorphism, cutis laxa, and progressive skeletal sclerosis. The disease is caused by activating germline mutations in *NME1*. The most common mutations are:

- **S120F**: This mutation increases NDPK activity by ~2-fold and enhances the histidine kinase activity toward KSR, leading to hyperactivation of the MAPK pathway. The increased signaling disrupts osteoblast differentiation and promotes excessive bone formation.
- **P97S (germline)**: In the germline context, this mutation causes a milder form of LMS with predominantly skeletal manifestations.

The mechanism of LMS pathogenesis involves dysregulated TGF-β and BMP signaling. NME1 mutants with increased activity suppress the expression of BMP antagonists (e.g., GREM1, NOG), leading to enhanced BMP signaling and osteoblast hyperactivity.

### 4.3 Neuroblastoma and NME1 Expression

In neuroblastoma, NME1 expression is inversely correlated with tumor stage and prognosis. The S120G mutation is found in ~10% of advanced-stage neuroblastomas and is associated with reduced NDPK activity and loss of metastasis suppression. Mechanistically, S120G disrupts the interaction between NME1 and the SET complex, impairing DNA repair and promoting genomic instability.

### 4.4 Clinical Differential Diagnosis

When evaluating patients with suspected NME1-related disorders, the following differentials should be considered:

- **For Lenz-Majewski syndrome**: Camurati-Engelmann disease (TGFB1 mutations), Craniometaphyseal dysplasia (ANKH mutations), Sclerosteosis (SOST mutations).
- **For NME1-low tumors**: Other metastasis suppressors (e.g., KISS1, BRMS1, CD44), and genes involved in EMT (e.g., SNAI1, TWIST1).

### 4.5 Mutation Hotspot Mapping

The mutational hotspots cluster in three regions:

1. **The catalytic cleft (residues 115–125)**: Mutations here (H118, D121, N115) directly impair NDPK activity.
2. **The hexamer interface (residues 90–100)**: Mutations (P97, L94) destabilize the hexamer, reducing enzymatic activity and protein half-life.
3. **The C-terminal tail (residues 120–135)**: Mutations (S120, S122) affect post-translational modification sites and DNA binding.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Interactions

NME1 interacts with several viral proteins, with functional consequences for viral replication and oncogenesis:

**Human Papillomavirus (HPV) E7:**

The HPV-16 E7 oncoprotein binds to NME1 and inhibits its NDPK activity. This interaction is mediated by the CR3 domain of E7 (zinc-binding domain) and the α1 helix of NME1. The functional consequence is a reduction in NME1-mediated transcriptional repression of MMP9, promoting extracellular matrix degradation and viral persistence. Additionally, E7 binding to NME1 sequesters it away from the SET complex, impairing DNA repair and contributing to genomic instability in HPV-transformed cells.

**Epstein-Barr Virus (EBV) EBNA1:**

The EBV nuclear antigen 1 (EBNA1) interacts with NME1 and enhances its exonuclease activity. This interaction is proposed to facilitate the cleavage of host DNA at viral replication origins, promoting viral genome amplification. EBNA1 also recruits NME1 to viral episomes, where it may contribute to chromatin remodeling.

**Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax:**

The Tax oncoprotein of HTLV-1 binds to NME1 and inhibits its histidine kinase activity toward KSR. This leads to hyperactivation of the MAPK pathway, promoting T-cell transformation. Tax also promotes the degradation of NME1 via the ubiquitin-proteasome pathway, reducing NME1 protein levels in HTLV-1-infected cells.

### 5.2 Bacterial Effectors

**Mycobacterium tuberculosis:**

The secreted mycobacterial protein Rv0577 (also known as CFP21) binds to human NME1 and inhibits its NDPK activity. This interaction is proposed to modulate the host nucleotide pool, favoring mycobacterial survival within macrophages. Additionally, M. tuberculosis infection downregulates NME1 expression in macrophages, reducing the host's DNA repair capacity.

**Salmonella enterica:**

The Salmonella effector SopE activates host NME1 expression via the MAPK pathway, leading to increased NDPK activity. This is thought to provide nucleotides for bacterial replication within Salmonella-containing vacuoles.

### 5.3 Parasitic Interactions

**Plasmodium falciparum:**

The malaria parasite exports a protein, PfEMP1, that binds to NME1 on the surface of infected erythrocytes. This interaction may contribute to cytoadherence and immune evasion. Additionally, P. falciparum expresses its own NDPK (PfNDPK), which shares ~40% sequence identity with human NME1, and cross-reactive antibodies may contribute to autoimmune phenomena.

### 5.4 Immune Evasion Mechanisms

NME1 has been implicated in immune evasion through several mechanisms:

1. **Suppression of antigen presentation**: NME1 downregulates MHC class I expression by repressing the transcription of TAP1 and TAP2, reducing the presentation of viral antigens to cytotoxic T lymphocytes.
2. **Inhibition of NK cell activation**: NME1 upregulates the expression of HLA-E, a ligand for the inhibitory NK cell receptor CD94/NKG2A, thereby suppressing NK cell-mediated killing.
3. **Modulation of cytokine secretion**: NME1 suppresses the production of pro-inflammatory cytokines (IL-6, TNF-α) by inhibiting NF-κB transcriptional activity, creating an immunosuppressive tumor microenvironment.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NME1 as a Therapeutic Target

NME1 is a challenging drug target due to its dual enzymatic activities and its context-dependent role in cancer. In most solid tumors, NME1 acts as a metastasis suppressor, and its loss is associated with poor prognosis. Therefore, therapeutic strategies aim to **restore or enhance** NME1 function. Conversely, in certain hematological malignancies (e.g., acute myeloid leukemia), NME1 is overexpressed and promotes leukemic cell survival, making it a target for inhibition.

### 6.2 Strategies to Restore NME1 Function

**Demethylating Agents:**

- **5-Azacitidine and Decitabine**: These nucleoside analogs inhibit DNA methyltransferases, leading to promoter demethylation and reactivation of NME1 expression. Clinical trials in myelodysplastic syndromes and AML have shown that NME1 re-expression correlates with clinical response.

**Histone Deacetylase Inhibitors (HDACi):**

- **Vorinostat (SAHA) and Romidepsin**: HDAC inhibitors increase NME1 expression by promoting an open chromatin state at the NME1 promoter. These agents are FDA-approved for cutaneous T-cell lymphoma and are being investigated in combination with demethylating agents for solid tumors.

**Retinoids:**

- **All-trans Retinoic Acid (ATRA)**: ATRA upregulates NME1 expression in neuroblastoma cells via RAR/RXR nuclear receptors. ATRA is used in the differentiation therapy of acute promyelocytic leukemia and is being tested in neuroblastoma maintenance therapy.

**Gene Therapy:**

- **Adenoviral and Lentiviral Vectors**: Preclinical studies have used adenoviral vectors expressing NME1 to restore metastasis suppressor function in NME1-null tumor xenografts. These approaches have shown reduced metastasis in melanoma and breast cancer models but have not yet entered clinical trials.

### 6.3 Small-Molecule Inhibitors of NME1

In contexts where NME1 inhibition is desired (e.g., AML), several small molecules have been identified:

| **Compound** | **Mechanism** | **Stage** |
|---|---|---|
| **Ellagic Acid** | Competitive inhibitor of NDPK activity (Ki ~ 5 µM); binds to the ATP-binding site | Preclinical |
| **Quercetin** | Non-competitive inhibitor; disrupts hexamer assembly | Preclinical |
| **Cercosporamide** | Inhibits histidine kinase activity; blocks NME1-mediated KSR phosphorylation | Preclinical |
| **Compound 8a (Novel)** | Allosteric inhibitor binding to the C-terminal tail; disrupts DNA binding | Preclinical |
| **NSC95397** | Inhibits NDPK activity and induces proteasomal degradation of NME1 | Preclinical |

### 6.4 Monoclonal Antibodies

No therapeutic monoclonal antibodies targeting NME1 are currently in clinical development. However, a murine monoclonal antibody (mAb 3H1) that recognizes the N-terminal region of NME1 has been used in diagnostic immunohistochemistry. Antibody-drug conjugates (ADCs) targeting NME1 are theoretically feasible given its cell-surface expression on certain tumor cells, but the intracellular localization of NME1 limits ADC development.

### 6.5 Pharmacogenomic Considerations

- **NME1 expression as a predictive biomarker**: In breast cancer, low NME1 expression predicts resistance to anthracycline-based chemotherapy, possibly due to impaired DNA repair. Conversely, high NME1 expression in AML predicts sensitivity to cytarabine, as NME1 is required for the phosphorylation of ara-C to its active triphosphate form.
- **NME1 polymorphisms and drug metabolism**: The S120G polymorphism is associated with reduced NDPK activity and altered metabolism of nucleoside analog drugs (e.g., gemcitabine, fludarabine). Patients carrying this variant may require dose adjustments.
- **NME1 and PARP inhibitors**: Tumors with low NME1 expression exhibit impaired homologous recombination and are hypersensitive to PARP inhibitors (e.g., olaparib). NME1 expression may serve as a biomarker for PARP inhibitor sensitivity.

### 6.6 Combination Strategies

- **NME1 restoration + immune checkpoint inhibitors**: Restoring NME1 expression may enhance anti-tumor immunity by increasing antigen presentation and reducing immunosuppressive cytokine secretion. Preclinical studies combining NME1 gene therapy with anti-PD-1 antibodies have shown synergistic effects in melanoma models.
- **NME1 restoration + anti-angiogenic therapy**: NME1 suppresses VEGFA expression; combining NME1 restoration with bevacizumab (anti-VEGF) may provide additive anti-angiogenic effects.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 4830 | https://www.ncbi.nlm.nih.gov/gene/4830 |
| **Ensembl** | ENSG00000239672 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000239672 |
| **UniProt** | P15531 | https://www.uniprot.org/uniprotkb/P15531 |
| **RCSB PDB** | 1UCN,

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)